Sales Of Three Major Pharmaceutical Cannabis Products Set To Reach €1.8 Billion By 2025 September 3, 2021 Peter McCusker Medical Marijuana 0 Comments COMBINED sales of the three most lucrative cannabis pharmaceuticals products – Epidiolex, Dronabinol and Sativex – are set to reach €1.8 billion by 2025, according to a new report. The Pharmaceutical Cannabis Report: 2nd Edition, from global cannabis industry consultants… Read More→
GW Pharmaceuticals plc Reports Fiscal Fourth Quarter and Year-End 2018 Financial Results and Operational Progress December 7, 2018 Press Release Banking, Finance & Real Estate, Press Releases, Science and Technology 0 Comments PRESS RELEASE Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine launched in the U.S. - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH,… Read More→
GW Pharmaceutical: A Cut Above the Rest September 28, 2016 Rob Meagher Company Stories, Science and Technology 0 Comments I think Forbes said it best in Debra Borchardt's recent article, "GW Pharmaceutical Gets Closer To Forcing FDA On Cannabis," with an  announcement a couple of weeks ago that its Clinical Phase 3 trial results for Epidolex were positive in paving… Read More→